Lilly to buy three vaccine developers for nearly $4 billion in infectious disease pushReuters • 05/26/26
Eli Lilly Just Got a Huge Vote of Confidence From Morgan Stanley -- and It's All About MounjaroThe Motley Fool • 05/25/26
Eli Lilly weight loss drug data supports long-term obesity market position, says UBSProactive Investors • 05/25/26
A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemiaPRNewsWire • 05/25/26
Eli Lilly Just Made a Game-Changing Move in the Billion-Dollar Weight Loss Drug Space. Here's What You Need to Know.The Motley Fool • 05/25/26
Novo Nordisk faces new GLP-1 rival as Eli Lilly's triple agonist sets weight-loss recordProactive Investors • 05/22/26
Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual MeetingPRNewsWire • 05/21/26
Can Mounjaro, Zepbound & Foundayo Keep Fueling LLY's Growth Story?Zacks Investment Research • 05/21/26
Eli Lilly's Next-Gen Obesity Drug Delivers Eye-Popping Weight LossInvestors Business Daily • 05/21/26